Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infectionopen access
- Authors
- Kim, Deok-Hwan; Lee, Jiho; Youk, Sungsu; Jeong, Jei-Hyun; Lee, Da-Ye; Ju, Hyo-Seon; Youn, Ha-Na; Kim, Jin-Cheol; Park, Soo-Bin; Park, Ji-Eun; Kim, Ji-Yun; Kim, Tae-Hyeon; Lee, Seung-Hun; Lee, Hyukchae; Abdal, Lah Mouhamed Abdallah Amal; Lee, Dong-Hun; Park, Pil-Gu; Hong, Kee-Jong; Song, Chang-Seon
- Issue Date
- Jul-2023
- Publisher
- ELSEVIER SCI LTD
- Keywords
- SARS-CoV-2; Newcastle disease virus-vectored vaccine; Intramuscular vaccine; Lung viral load; K18-hACE-2 TG mice
- Citation
- VACCINE, v.41, no.33, pp.4787 - 4797
- Journal Title
- VACCINE
- Volume
- 41
- Number
- 33
- Start Page
- 4787
- End Page
- 4797
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/89027
- DOI
- 10.1016/j.vaccine.2023.05.071
- ISSN
- 0264-410X
- Abstract
- Coronavirus disease 2019 (Covid-19) caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) became a pandemic, causing significant burden on public health worldwide. Although the timely development and production of mRNA and adenoviral vector vaccines against SARS-CoV-2 have been successful, issues still exist in vaccine platforms for wide use and production. With the potential for proliferative capability and heat stability, the Newcastle disease virus (NDV)-vectored vaccine is a highly economical and conceivable candidate for treating emerging diseases. In this study, a recombinant NDV-vectored vaccine expressing the spike (S) protein of SARS-CoV-2, rK148/beta-S, was developed and evaluated for its efficacy against SARS-CoV-2 in K18-hACE-2 transgenic mice. Intramuscular vaccination with low dose (106.0 EID50) conferred a survival rate of 76 % after lethal challenge of a SARS-CoV-2 beta (B.1.351) variant. When administered with a high dose (107.0 EID50), vaccinated mice exhibited 100 % survival rate and reduced lung viral load against both beta and delta variants (B.1.617.2). Together with the protective immunity, rK148/beta-S is an accessible and cost-effective SARS-CoV-2 vaccine. & COPY; 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의예과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/89027)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.